• Mashup Score: 0
    lock - 6 month(s) ago

    Medicare Drug Price Negotiation Program Patient-Focused Listening Sessions  

    Tweet Tweets with this article
    • Last chance to make your voice heard! If you use any of these medications, sign up to advocate for the lower prices you need: #Eliquis, #Jardiance, #Xarelto, #Januvia, #Farxiga, #Entresto, #Enbrel, #Imbruvica, #Stelara, #Fiasp, #NovoLog Learn more: https://t.co/vWjSB5TtV6

  • Mashup Score: 0

    In a Healio video exclusive, Maria T. Abreu, MD, outlined long-term data presented at the European Crohn’s and Colitis Congress on the use of Stelara among patients with inflammatory bowel disease. Results from the UNIFI study (n = 205 patients) showed ustekinumab (Stelara, Janssen) induced clinical response (80%), modified Mayo score response (79.5%), endoscopic improvement (67.3%) and

    Tweet Tweets with this article
    • In a @GoHealio #GI #video exclusive, @ibddocmaria outlined long-term data presented at #ECCO23 on the use of #Stelara (@JanssenUS) among #patients with #IBD #GITwitter #MedTwitter https://t.co/g1Ev1yszFR

  • Mashup Score: 0

    VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis. According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At

    Tweet Tweets with this article
    • #ICYMI from #UEGWeek 2022: #Stelara safe, effective for the long-term treatment of moderate to severe #UC @my_ueg #GITwitter #MedTwitter https://t.co/2PvgZV56jh

  • Mashup Score: 1

    VIENNA — In a Healio video exclusive, Waqqas Afif, MD, reports results from the phase 3 UNIFI study, in which Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with ulcerative colitis. According to Afif, 65% of patients who responded to the induction dose of Stelara (ustekinumab, Janssen) were in remission after 44 weeks of maintenance therapy. At

    Tweet Tweets with this article
    • In a Healio video exclusive, @waqqasafif reports results presented at #UEGWeek 2022 from the phase 3 #UNIFI study, in which #Stelara safely demonstrated sustained symptomatic and corticosteroid-free remission in adults with #ulcerativecolitis #UC @my_ueg https://t.co/2PvgZV56jh

  • Mashup Score: 2

    In a Healio video exclusive, Remo Panaccione, MD, discusses results from long-term, pooled analyses of adult patients treated with ustekinumab for inflammatory bowel disease. “We know that Stelara (ustekinumab, Janssen) is a highly effective therapy in inflammatory bowel disease when it’s either used first-line or in patients who have been exposed to other advanced therapies,”

    Tweet Tweets with this article
    • #ICYMI: "“We know that #Stelara (#ustekinumab, @JanssenUS) is a highly effective therapy in #IBD when it's either used first-line or in patients who have been exposed to other advanced therapies,” @RPanaccione told Healio #GITwitter #MedTwitter https://t.co/cReeKxB963

  • Mashup Score: 5

    In a video exclusive, Subrata Ghosh, MD, of the University College Cork, reported older patients with inflammatory bowel disease treated with Stelara did not experience increased rates of serious adverse events compared with placebo. “In clinical practice, prescribing older IBD patients is a challenge; about 25% to 35% of our IBD population now are over the age of 60 years and this

    Tweet Tweets with this article
    • #ICYMI: #Stelara safe in treatment of older patients with #IBD #GITwitter #MedTwitter https://t.co/mgtw3nTRK9

  • Mashup Score: 3

    In a video exclusive, Subrata Ghosh, MD, of the University College Cork, reported older patients with inflammatory bowel disease treated with Stelara did not experience increased rates of serious adverse events compared with placebo. “In clinical practice, prescribing older IBD patients is a challenge; about 25% to 35% of our IBD population now are over the age of 60 years and this

    Tweet Tweets with this article
    • VIDEO: #Stelara safe in treatment of older patients with #IBD #GITwitter #MedTwitter https://t.co/mgtw3nTRK9

  • Mashup Score: 0

    Entyvio and Stelara were commonly used in combination therapy for the treatment of inflammatory bowel disease, according to research at Digestive Disease Week. “When used with an immunomodulator (ie, azathioprine, methotrexate), anti-TNFs are associated with lower rates of anti-drug antibodies and increased rates of clinical remission but also with increased rates of infections,”

    Tweet Tweets with this article
    • #ICYMI: Count down our #top5 stories from #June2021, featuring research from #DDW2021 and #ILC2021. Our second top story of the month reported on combination therapy commonly used with #Entyvio, #Stelara: https://t.co/iew23Z17DZ